NYSE:EBS Emergent Biosolutions (EBS) Stock Price, News & Analysis $8.14 +0.08 (+0.93%) As of 02:26 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Emergent Biosolutions Stock (NYSE:EBS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Emergent Biosolutions alerts:Sign Up Key Stats Today's Range$8.06▼$8.4050-Day Range$7.84▼$9.5052-Week Range$5.61▼$14.06Volume222,462 shsAverage Volume855,112 shsMarket Capitalization$420.09 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingHold Company Overview Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs. Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal. The company invests in research and development to expand its pipeline of vaccines and therapeutics, with particular emphasis on next-generation platforms and novel delivery approaches. Emergent operates research, development and manufacturing facilities in North America, Europe and Asia. Its primary U.S. manufacturing sites in Maryland and Michigan produce both licensed products and countermeasures under contract, while additional sites and partnerships support global distribution. Through a network of collaborations and supply agreements, Emergent serves government health agencies, commercial customers and international markets to ensure availability of its critical medical products. Founded in 1998 (originally as BioPort) and renamed Emergent BioSolutions in 2004, the company is led by President and Chief Executive Officer Robert G. Kramer Jr. Under his leadership, Emergent has expanded its contract manufacturing footprint, strengthened its commercial portfolio and advanced strategic initiatives in pandemic preparedness. The company remains focused on leveraging its expertise in biodefense and public health to address evolving global health challenges.AI Generated. May Contain Errors. Read More Emergent Biosolutions Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreEBS MarketRank™: Emergent Biosolutions scored higher than 31% of companies evaluated by MarketBeat, and ranked 738th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingEmergent Biosolutions has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialEmergent Biosolutions has a consensus price target of $12.00, representing about 44.0% upside from its current price of $8.34.Amount of Analyst CoverageEmergent Biosolutions has only been the subject of 2 research reports in the past 90 days.Read more about Emergent Biosolutions' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Emergent Biosolutions is -29.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Emergent Biosolutions is -29.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEmergent Biosolutions has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Emergent Biosolutions' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.14% of the float of Emergent Biosolutions has been sold short.Short Interest Ratio / Days to CoverEmergent Biosolutions has a short interest ratio ("days to cover") of 18.42, which indicates bearish sentiment.Change versus previous monthShort interest in Emergent Biosolutions has recently increased by 1.36%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEmergent Biosolutions does not currently pay a dividend.Dividend GrowthEmergent Biosolutions does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Emergent Biosolutions this week, compared to 3 articles on an average week.Search Interest5 people have searched for EBS on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Emergent Biosolutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $518,312.00 in company stock.Percentage Held by Insiders6.00% of the stock of Emergent Biosolutions is held by insiders.Percentage Held by Institutions78.40% of the stock of Emergent Biosolutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Emergent Biosolutions' insider trading history. Receive EBS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emergent Biosolutions and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EBS Stock News HeadlinesEmergent BioSolutions to Participate in Upcoming Investor ConferencesMay 20 at 7:30 AM | globenewswire.comEmergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]May 18 at 8:59 AM | globenewswire.comNo. You’re not imagining it…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.May 20 at 1:00 AM | Porter & Company (Ad)Hantavirus cases spark surge in pharma and biotech stocks — here's whyMay 11, 2026 | cnbc.comSujata Tyagi Dayal Sells 13,761 Shares of Emergent Biosolutions (NYSE:EBS) StockMay 5, 2026 | insidertrades.comEmergent BioSolutions Inc (EBS) Q1 2026 Earnings Call Highlights: Strong Revenue and Strategic ...May 2, 2026 | finance.yahoo.comEmergent BioSolutions Earnings Call Highlights Turnaround MomentumMay 1, 2026 | tipranks.comEmergent BioSolutions Reports First Quarter 2026 Financial ResultsApril 30, 2026 | globenewswire.comSee More Headlines EBS Stock Analysis - Frequently Asked Questions How have EBS shares performed this year? Emergent Biosolutions' stock was trading at $12.35 on January 1st, 2026. Since then, EBS stock has decreased by 32.5% and is now trading at $8.3350. How were Emergent Biosolutions' earnings last quarter? Emergent Biosolutions Inc. (NYSE:EBS) issued its quarterly earnings data on Thursday, April, 30th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating the consensus estimate of ($0.25) by $0.46. The biopharmaceutical company had revenue of $156.10 million for the quarter, compared to analyst estimates of $145 million. Emergent Biosolutions had a positive trailing twelve-month return on equity of 10.76% and a negative net margin of 1.27%. Read the conference call transcript. Is Emergent Biosolutions doing a stock buyback? Emergent Biosolutions' board initiated a share repurchase plan on Monday, March 31st 2025, which permits the company to repurchase $50,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 19% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's management believes its shares are undervalued. Who are Emergent Biosolutions' major shareholders? Top institutional shareholders of Emergent Biosolutions include Dimensional Fund Advisors LP (5.34%), Renaissance Technologies LLC (1.27%), Values First Advisors Inc. (0.60%) and Cetera Investment Advisers (0.44%). Insiders that own company stock include Coleen Glessner, Donald W Degolyer, Neal Franklin Fowler, Sujata Tyagi Dayal, Ronald Richard, Keith Katkin and Kathryn C Zoon. View institutional ownership trends. How do I buy shares of Emergent Biosolutions? Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Emergent Biosolutions own? Based on aggregate information from My MarketBeat watchlists, some other companies that Emergent Biosolutions investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Alibaba Group (BABA) and Moderna (MRNA). Company Calendar Last Earnings4/30/2026Today5/20/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 EBS's financial health is in the Green zone, according to TradeSmith. EBS has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNYSE:EBS CIK1367644 Webwww.emergentbiosolutions.com Phone(240) 631-3200Fax301-795-1899Employees2,420Year FoundedN/APrice Target and Rating Average Price Target for Emergent Biosolutions$12.00 High Price Target$12.00 Low Price Target$12.00 Potential Upside/Downside+43.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$52.60 million Net Margins-1.27% Pretax Margin0.52% Return on Equity10.76% Return on Assets4.22% Debt Debt-to-Equity Ratio1.10 Current Ratio4.29 Quick Ratio2.08 Sales & Book Value Annual Sales$742.90 million Price / Sales0.58 Cash Flow$3.77 per share Price / Cash Flow2.22 Book Value$10.13 per share Price / Book0.83Miscellaneous Outstanding Shares51,640,000Free Float48,545,000Market Cap$431.97 million OptionableOptionable Beta2.33 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NYSE:EBS) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | SponsoredSaudi Arabia just broke its 50-year dollar arrangementSaudi Arabia has quietly walked away from its 1974 petrodollar agreement with the U.S. - the pact that require...Golden Portfolio | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredThis Biotech Just Flipped From Story to ExecutionAvai Bio (OTCQB: AVAI) has moved into production on its new Master Cell Bank, developed alongside Austrianova,...Equiscreen | SponsoredForget SpaceX. Buy the company Musk can't replace.The SpaceX IPO is expected to price at $1.75 trillion - and retail investors won't get an allocation. Banks an...Behind the Markets | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emergent Biosolutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emergent Biosolutions With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
